Related Experiment Videos

Soft-tissue venous malformations in children: percutaneous sclerotherapy with Ethibloc

J M Dubois1, G H Sebag, Y De Prost

  • 1Department of Pediatric Radiology, Hôpital des Enfants Malades, Paris, France.

Radiology
|July 1, 1991
PubMed

Insights

Percutaneous Ethibloc injections effectively treated soft-tissue venous malformations (VMs) in children. This minimally invasive approach achieved good or excellent results in 74% of cases with few side effects.

Area of Science:

  • Vascular Surgery
  • Pediatric Surgery
  • Interventional Radiology

Background:

  • Soft-tissue venous malformations (VMs) are common congenital vascular anomalies in children.
  • Traditional treatments for VMs can be invasive and associated with significant morbidity.
  • There is a need for effective, minimally invasive treatment options for pediatric VMs.

Purpose of the Study:

  • To evaluate the efficacy and safety of percutaneous Ethibloc injection for treating soft-tissue venous malformations in children.
  • To assess the technique, outcomes, side effects, and complications associated with this novel fibrosing agent.

Main Methods:

  • Thirty-eight children with soft-tissue VMs underwent percutaneous injection of Ethibloc.
  • The procedure involved direct puncture of the malformation for evaluation and injection.
  • Treatment was performed either as a standalone procedure or in conjunction with surgery.

Main Results:

  • Good or excellent results were achieved in 74% of the treated cases.
  • Complete cure was observed in 50% of the patients.
  • The procedure was associated with minimal side effects and no major complications.

Conclusions:

  • Percutaneous Ethibloc injection is a safe and effective treatment for pediatric soft-tissue venous malformations.
  • This minimally invasive technique offers a high success rate with a favorable safety profile.
  • Ethibloc represents a promising new therapeutic option for managing VMs in children.

Related Concept Videos